277 related articles for article (PubMed ID: 22913825)
21. Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
Gautier-Veyret E; Bäck M; Arnaud C; Belaïdi E; Tamisier R; Lévy P; Arnol N; Perrin M; Pépin JL; Stanke-Labesque F
Pharmacol Res; 2018 Aug; 134():311-319. PubMed ID: 29920371
[TBL] [Abstract][Full Text] [Related]
22. Leukotriene signaling in atherosclerosis and ischemia.
Bäck M
Cardiovasc Drugs Ther; 2009 Feb; 23(1):41-8. PubMed ID: 18949546
[TBL] [Abstract][Full Text] [Related]
23. Enzymes and receptors in the leukotriene cascade.
Haeggström JZ; Wetterholm A
Cell Mol Life Sci; 2002 May; 59(5):742-53. PubMed ID: 12088275
[TBL] [Abstract][Full Text] [Related]
24. Leukotriene modifiers in the treatment of cardiovascular diseases.
Riccioni G; Capra V; D'Orazio N; Bucciarelli T; Bazzano LA
J Leukoc Biol; 2008 Dec; 84(6):1374-8. PubMed ID: 18794213
[TBL] [Abstract][Full Text] [Related]
25. The role of leukotrienes in allergic diseases.
Liu M; Yokomizo T
Allergol Int; 2015 Jan; 64(1):17-26. PubMed ID: 25572555
[TBL] [Abstract][Full Text] [Related]
26. [The role of cysteinyl leukotrienes in chronic inflammation and neoplasia of the intestine].
Broom OJ; Nielsen OH
Ugeskr Laeger; 2009 Jan; 171(4):243-6. PubMed ID: 19174041
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological inhibition of leukotriene biosynthesis: effects on the heart conductance.
Sanak M; Dropinski J; Sokolowska B; Faber J; Rzeszutko M; Szczeklik A
J Physiol Pharmacol; 2010 Feb; 61(1):53-8. PubMed ID: 20228415
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids.
Rubin P; Mollison KW
Prostaglandins Other Lipid Mediat; 2007 May; 83(3):188-97. PubMed ID: 17481554
[TBL] [Abstract][Full Text] [Related]
29. The Role of Leukotrienes as Potential Therapeutic Targets in Allergic Disorders.
Jo-Watanabe A; Okuno T; Yokomizo T
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336653
[TBL] [Abstract][Full Text] [Related]
30. Structures and mechanisms of enzymes in the leukotriene cascade.
Rinaldo-Matthis A; Haeggström JZ
Biochimie; 2010 Jun; 92(6):676-81. PubMed ID: 20097252
[TBL] [Abstract][Full Text] [Related]
31. Human bronchial fibroblasts express the 5-lipoxygenase pathway.
James AJ; Penrose JF; Cazaly AM; Holgate ST; Sampson AP
Respir Res; 2006 Jul; 7(1):102. PubMed ID: 16872537
[TBL] [Abstract][Full Text] [Related]
32. Treatment of asthma with drugs modifying the leukotriene pathway.
Drazen JM; Israel E; O'Byrne PM
N Engl J Med; 1999 Jan; 340(3):197-206. PubMed ID: 9895400
[No Abstract] [Full Text] [Related]
33. Functional characterisation of receptors for cysteinyl leukotrienes in smooth muscle.
Jonsson EW
Acta Physiol Scand Suppl; 1998 Mar; 641():1-55. PubMed ID: 9597121
[TBL] [Abstract][Full Text] [Related]
34. Cysteinyl leukotrienes and leukotriene B mediate vasoconstriction to arginine vasopressin in rat basilar artery.
Trandafir CC; Nishihashi T; Ji X; Wang A; Kurahashi K
Clin Exp Pharmacol Physiol; 2005 Dec; 32(12):1027-33. PubMed ID: 16445567
[TBL] [Abstract][Full Text] [Related]
35. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease.
Poeckel D; Funk CD
Cardiovasc Res; 2010 May; 86(2):243-53. PubMed ID: 20093252
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological modulation of the leukotriene pathway in allergic airway disease.
Montuschi P; Sala A; Dahlén SE; Folco G
Drug Discov Today; 2007 May; 12(9-10):404-12. PubMed ID: 17467577
[TBL] [Abstract][Full Text] [Related]
37. Studies of receptors and modulatory mechanisms in functional responses to cysteinyl-leukotrienes in smooth muscle.
Bäck M
Acta Physiol Scand Suppl; 2002 Feb; 648():1-55. PubMed ID: 11913222
[TBL] [Abstract][Full Text] [Related]
38. Leukotriene production profiles and actions in the bovine endometrium during the oestrous cycle.
Korzekwa AJ; Milewski R; Łupicka M; Skarzynski DJ
Reprod Fertil Dev; 2016 Apr; 28(6):682-9. PubMed ID: 25483008
[TBL] [Abstract][Full Text] [Related]
39. Modulation of leukotriene signaling inhibiting cell growth in chronic myeloid leukemia.
Yektaei-Karin E; Zovko A; Nilsson A; Näsman-Glaser B; Kanter L; Rådmark O; Wallvik J; Ekblom M; Dolinska M; Qian H; Stenke L
Leuk Lymphoma; 2017 Aug; 58(8):1903-1913. PubMed ID: 27931141
[TBL] [Abstract][Full Text] [Related]
40. Pharmacological cross-reactivity between 5-lipoxygenase-activating protein, 5-lipoxygenase, and leukotriene C4 synthase.
Gupta N; Nicholson DW; Ford-Hutchinson AW
Can J Physiol Pharmacol; 1997; 75(10-11):1212-9. PubMed ID: 9431445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
